MRD-directed Therapy for Low-risk and Intermediate-risk AML.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

743

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

December 31, 2019

Conditions
Acute Myeloid LeukemiaMinimal Residual Disease
Interventions
COMBINATION_PRODUCT

MRD-directed therapy

The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.

Trial Locations (1)

510515

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Guangzhou First People's Hospital

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02870777 - MRD-directed Therapy for Low-risk and Intermediate-risk AML. | Biotech Hunter | Biotech Hunter